Background
==========

Around the world, infection by the Hepatitis C virus (HCV) causes acute and chronic liver disease and may lead to cirrhosis, liver failure and/or hepatocellular carcinoma. HCV chronic liver disease is one of the main causes of liver transplantation in developed countries \[[@B1]\]. The global prevalence of HCV infection is estimated to be 2.2%, with 170 million individuals infected (2004) \[[@B2]\].

The sequential population-based studies conducted in the USA are among the few nationwide surveys to estimate the prevalence of HCV \[[@B3]-[@B6]\]. In the USA, a 1.6% nationwide prevalence of anti-HCV was found by the National Health and Nutrition Examination Survey Continuous (NHANES Continuous) between 1999 and 2002 \[[@B5]\]. These surveys showed a decline in the prevalence of hepatitis C from NHANES III (1988--1994) to NHANES Continuous (2003--2006), but this figure remained stable between the NHANES 1999--2002 and NHANES 2003--2006 \[[@B6]\]. The incidence of acute hepatitis C tended to decline over the twenty-five years of surveillance (1982--2006) in selected counties in the USA, with intravenous drug use (IDU) continuing to be the predominant risk factor \[[@B7]\]. In France, a population-based survey showed an overall prevalence of anti-HCV of 0.84% in 2004. IDU, nasal drug use, blood transfusion prior to 1992, having a tattoo, being older than 29 years, social deprivation, and being born on a continent with endemic levels higher than 2.5% were the risk factors associated with HCV infection \[[@B8]\].

In Latin America, estimates of HCV prevalence range from 1.0 to 2.3% using projections of HCV for modeling \[[@B9]\]. Data from the World Health Organization (WHO) placed Brazil among the countries with a prevalence of hepatitis C infection ranging from 2.5% to 10% \[[@B2]\]. Compulsory notification of acute and/or chronic hepatitis C was implemented by the Brazilian surveillance system in 1996. The detection rates for anti-HCV remained stable at approximately 10 cases per 100,000 individuals from 2004 to 2009, with the bulk of cases being reported in the southeast region \[[@B10]\]. In Brazil, the few population-based studies \[[@B11]-[@B13]\] and the vast majority of studies reporting risk factors associated with HCV infection were obtained from selected populations in restricted areas \[[@B14]-[@B18]\]. In a large sample of chronic HCV patients from different laboratories located in all Brazilian macro-regions, genotype 1 was found to predominate, followed by genotypes 3, 2, 4 and 5 \[[@B19]\].

A national seroepidemiological survey of Hepatitis A, B and C infection was launched by the Brazilian Ministry of Health in 2005 and completed in 2009. The epidemiology of hepatitis A and hepatitis B for the northeast and central-west regions and the Federal District has already been published \[[@B20],[@B21]\]. The aim of the present study was to estimate the seroprevalence of HCV antibodies in the five macro-regions of Brazil and the Federal District. The association between potential risk factors and HCV seropositivity was assessed for the country as a whole and the population attributable risk for multiple factors was estimated using the case--control approach. This is the first population-based HCV antibody survey conducted in a representative sample of the Brazilian macro-regions and the Federal District.

Methods
=======

Study design and sites
----------------------

The national seroepidemiological survey of hepatitis A, B and C infection was designed as a representative sample of individuals aged 10 to 19 and 20 to 69 years in the 5 Brazilian macro-regions. Participants were residents of all 26 State capitals and the Federal District. The fieldwork was conducted from 2005 to 2009. The methodology has been described in a prior publication \[[@B22]\].

In brief, a stratified multistage cluster sampling method based on The Brazilian Institute of Geography and Statistics (IBGE) census data for the year 2000 was used to select the study population. In the first step, within each macro-region, the sample was stratified by state capital using a constant sampling fraction. In the second step the primary sampling units -- census tracts -- were drawn with probability proportional to population size and assuring the inclusion of all socioeconomic groups. The primary sampling units were subsampled successively in terms of blocks (with probability proportional to population size), households and eligible individuals. The final analysis weights incorporated the selection probabilities and design effect due to the cluster sampling to obtain representative estimates of the target population.

Data collection and variables
-----------------------------

All sites followed the same standard protocol. Data were collected by interview using a structured questionnaire during household visits. Blood samples were collected after the interviews. Both procedures were performed by trained health personnel.

The individual variables collected were social-demographic characteristics, blood route-related factors, such as dental treatment, surgery, history of blood transfusion, hospitalization, endoscopy, use of glass syringe not related with drug abuse, tattoos, or body piercing. Questions related to alcohol, drug consumption, lifelong sexual behavior and health-related jobs were restricted to persons aged 13 years or older. At the household level, data on income and education of the head of family and the characteristics of the household including home ownership, water supply, sewage and solid waste disposal were recorded \[[@B22]\].

Serum tests and definitions
---------------------------

Blood samples were collected, transported and stored according to standard procedures. HCV antibodies were detected by a third-generation (Axsym, Abbott Laboratories, Abbott Park, Illinois) enzyme immunoassay in central public health laboratories. The results were considered positive when the optical density (OD) was ≥ 1.2 (20% higher than the cutoff). Samples with OD between 1.0 and 1.19 were considered indeterminate and were retested by anti-HCV; if the second testing yielded an indeterminate result, the sample was considered as negative. Seropositive individuals were submitted to a new blood sample collection to perform PCR and genotyping tests for clinical approach.

HCV RNA detection and genotyping
--------------------------------

HCV RNA was detected using AMPLICOR™ (Roche Version 2.0) and extracted from 200 μL serum using the extraction reagents included in the kit, in accordance with the manufacturer's instructions.

A commercially available reverse hybridization-based line probe assay (HCV Genotype assay, LiPA™) was employed, using Amplicor's PCR product generation. The genotypes were identified following the manufacturer's instructions.

Sample size
-----------

The sample size was based on the expected prevalence of seropositivity for anti-HCV according to data from blood donors by macro-region \[[@B23]\]. The variance was estimated as 20% of the prevalence value for all macro-regions and 30% for the Federal District \[[@B22]\]. The sample size achieved in this study matched the number of individuals estimated for each region and age group as previously reported.

As in the original protocol the analysis of risk factors for anti-HCV positivity was planned for the entire country, the number of seropositive individuals identified by the survey was large enough to detect differences in exposure corresponding to an odds ratio of 2, with a frequency of exposure among those not sick of 5% or more, a power of 80% and an alpha of 5%.

Statistical analysis
--------------------

Prevalence of anti-HCV with 95% confidence intervals (95% CI) was calculated for the country, by age group and by the five macro-regions and the Federal District. The estimated number of persons infected was based on the prevalence and on the census population official data of residents from the State Capitals by age groups for the year 2000 \[[@B24]\]. Prevalence was adjusted for the design effect and, when necessary, for regional variations in sample fractions.

The distributions of potential risk factors and their respective 95% CIs were calculated for the population aged 13 to 69 years old by macro-region. Possible associations between HCV infection and potential risk factors were assessed by calculating the Odds Ratio (OR), (95% CI) and p-values. ORs were adjusted for the design effect and age, and weighted for variations in sample fractions in the different age groups and regions. Variables that were associated with the outcome in this age-adjusted analysis (p \< 0.10) were included in a multivariate regression model by means of the Generalized Linear and Latent Mixed Models (GLLAMM). The two-level analysis (individual and household) was performed using Stata 9.2 \[[@B25]\]. Population attributable risk---the fraction of disease in the total study population that is attributable to the exposure--- was estimated for multiple factors using case--control data according to Bruzzi *et al*. \[[@B26]\]. Population attributable risk was also calculated for the ensemble of variables using an accepted procedure; it is worth noting that this estimate is not the equivalent of adding the population attributable risks for individual factors \[[@B26]\].

A ROC curve was plotted to predict viremia for the North macro-region, and to determine the cut-off for anti-HCV positivity using the Sample rate/cut-off rate (S/CO) ratios from the individuals tested for HCV-RNA.

Ethical issues
--------------

Interviews and blood sample collection were conducted after written consent forms had been signed. For minors, the legal guardian's consent was obtained. The project was approved by the National Research Ethics Committee (CONEP) of the Brazilian National Health Council and by the local Research Ethics Committees in each capital city.

Each positive result was communicated by the medical doctor in charge of the field research and the negative results were sent by mail. Individuals who had a positive result were sent to referral services in each State capital or the Federal District for further clinical evaluation.

Results
=======

Of 19,503 individuals aged 10 to 69 years old recruited, 2,288 were in the North region (Amazon area); 3,690 in the North-east; 3,702 in the Central-west; 1,988 in the Federal District; 3,661 in the South-east and 4,174 in the South. Of the total sample, 49.0% of the participants were aged 10--19 years old (n = 9,371) and 51.0% were 20--69 (n = 10,132). Females accounted for 54.6% of the total participants. The overall refusal rate was 2.8%, being below 1.5% for the North, Northeast and Central-west macro-regions and approximately 6% in the South and Southeast macro-regions.

In Brazil, the overall weighted prevalence of HCV antibodies was 1.38% (95% CI 1.12%--1.64%) in the state capitals of the five macro-regions and the Federal District taken as a whole (Table [1](#T1){ref-type="table"}). Seropositivity varied from 0.68% in the Northeast to 2.10% in the North region. In all macro-regions studied, adults (aged 20--69 years) had a higher prevalence of HCV antibodies than the younger age-group. The highest prevalence in adults was in the North region (3.22%; 95% CI 2.03%--4.41%). Prevalence peaked in those aged ≥ 60 years.

###### 

Prevalence of hepatitis C antibodies and estimated population ever-infected in a representative sample of individuals living in the state capitals of Brazil, 2005--2009

  **Setting age-group**   **Participants**   **Prevalence\* % (95% CI**)   **State capitals population**   **Estimated persons ever infected n (95% CI**)
  ----------------------- ------------------ ----------------------------- ------------------------------- ------------------------------------------------
  Brazil                                                                                                    
   10 -- 19               9,371              0.75 (0.53 -- 0.98)†          7,565,695                       56,970 (39,947 -- 74,068)
   20 -- 39               5,552              1.36 (1.02 -- 1.71)†          13,828,140                      188,478 (140,494 -- 236,462)
   40 -- 59               3,719              1.55 (1.09 -- 2.01)†          7,941,985                       122,783 (86,250 -- 159,396)
   60 -- 69               891                3.41 (2.03 -- 4.79)†          1,916,570                       65,432 (38,964 -- 91,900)
  North                                                                                                     
   10 -- 19               1,153              0.99 (0.36 --1.63)            860,922                         8,601 (3,117 -- 14,093)
   20 -- 69               1,135              3.22 (2.02 -- 4.41)           2,093,269                       67,403 (42,472 -- 92,334)
  Northeast                                                                                                 
   10 -- 19               1,840              0.38 (0.10 -- 0.66)           2,054,539                       7,848 (2,096 -- 13,601)
   20 -- 69               1,850              0.97 (0.48 -- 1.47)           5,358,923                       52,249 (25,616 -- 78,883)
  Midwest                                                                                                   
   10 -- 19               1,803              0.99 (0.53 -- 1.47)           866,536                         8,657 (4,601 -- 12,712)
   20 -- 69               1,899              1.64 (1.14 -- 2.13)           1,326,575                       21,703 (15,110 -- 28,296)
  Federal District                                                                                          
   10 -- 19               980                0.61 (0.13 -- 1.09)           387,831                         2,374 (524 -- 4,227)
   20 -- 69               1,008              1.09 (0.50 -- 1.68)           1,202,183                       13,116 (6,011 -- 20,245)
  Southeast                                                                                                 
   10 -- 19               1,794              0.90 (0.49 -- 1.31)           3,295,110                       29,755 (16,212 -- 43,298)
   20 -- 69               1,867              1.63 (1.07 -- 2.18)           11,661,984                      189,857 (124,783 -- 254,814)
  South                                                                                                     
   10 -- 19               1,801              0.51 (0.12 -- 0.89)           586,270                         2,978 (715 -- 5,241)
   20 -- 69               2,373              1.70 (1.08 -- 2.32)           2,043,761                       34,826 (22,175 -- 47,456)

\* Prevalence adjusted for random effect.

† Prevalence adjusted for random effect and weighted by regions.

The estimated number of persons ever infected in the Brazilian State capitals and Federal District was 430,658 (95% CI 349,714--511,289), based on the HCV prevalence and the size of the population. The largest infected population was in the Southeast region (190,254; 95% CI 136,110--244,548).

For the overall data set, anti-HCV positivity was similar between genders according to the two age strata (Figure [1](#F1){ref-type="fig"}). When stratified by macro-region, anti-HCV prevalence was similar between men and women in most of the studied settings, except in the Central-West macro-region, where men had a statistically significant higher prevalence of HCV infection than women (chi-square = 4.9, p \< 0.03) (Figure [1](#F1){ref-type="fig"}).

![Prevalence of hepatitis C infection in a representative sample of State capitals of the five Brazilian regions by sex and age group.](1471-2334-13-60-1){#F1}

Of 9,671 households investigated, ten contained two individuals testing positive for anti-HCV and one household contained three. Thirty participants were simultaneously seropositive for anti-HCV and anti-HBc antibodies.

Of 236 anti-HCV positive individuals, 120 (50.8%) had their blood collected for HCV-RNA testing in all the macro-regions and Federal District, with the exception of the North macro-region, owing to operational constraints. Of those retested, 36.7% (95% IC 28.4%-45.6%) were HCV-RNA positive. The ROC curve suggested that the cut-off point of 0.4, which yielded the higher sensitivity and specificity, was OD = 4.0. Using this parameter, 32.1% individuals would also be considered infected, that is, HCV-RNA positive, in the North region. The comparison of the participants who were retested (n = 120) versus those not retested (n = 116) in relation to variables associated with HCV infection that remained in the multivariate model showed that both groups were similar in terms of age group, use of injected and sniffed drugs, use of glass syringes and hospitalization. The main difference was in socio-economic conditions (chi-square = 8.8, p = 0.012) suggesting that those better-off were more likely to be retested. Assuming the frequency of HCV-RNA-positive individuals among the estimated persons ever infected in the present study, it would be expected that there were approximately 158,000 (122,000 to 196,000) patients infected with HCV.

The genotypes and subgenotypes detected were 1 (n = 3); 1a (n = 9); 1b (n = 16); 2b (n = 2); 3a (n = 14).

Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} show the age-adjusted odds ratio for the association between blood-related variables, sexual behavior and drug use and HCV infection for all the State capitals taken together. There was a positive association between anti-HCV antibodies and ever having received a blood transfusion (OR = 1.83, 95% CI 1.01--3.30), having been hospitalized in the previous 12 months (OR = 1.87, 95% CI 1.04--3.38), or having had a tattoo (OR = 1.63, 95% CI 0.95--2.80), the latter presenting a borderline p value (Table [2](#T2){ref-type="table"}). Having a current partner with hepatitis was positively associated with HCV antibodies and negatively associated with partner history of STD (Table [3](#T3){ref-type="table"}). Ever having used injected drugs was strongly associated with HCV antibodies (OR = 12.79, 95% CI 5.19--31.50). A statistically significant association was also found with ever having used sniffed drugs (OR = 3.50, 95% CI 1.87--6.54) and previous use of a glass syringe (OR = 1.67, 95% CI 1.09--2.56) (Table [4](#T4){ref-type="table"}). As for socioeconomic variables, sewage disposal (lack of sewage system versus public system) was associated with HCV antibodies (OR = 1.90, 95% CI 1.06--3.40).

###### 

Age-adjusted odds ratio of hepatitis C infection for blood route-related factors in the urban Brazilian population

  **Risk factors**          **Participants**   **HCV infection n (%)**   **OR**~**adjusted**~**(CI)\***   **p-value**
  ------------------------- ------------------ ------------------------- -------------------------------- -------------
  Dental treatment                                                                                         
   Never                    2,034              22 (1.1)                  1.0                              \-
   Past 12 months           8,655              99 (1.1)                  0.77 (0.41 -- 1.47)              0.436
   Ever                     8,772              114 (1.3)                 0.91 (0.47 -- 1.77)              0.795
  Surgery                                                                                                  
   Never                    11,481             108 (0.9)                 1.0                              \-
   Past 12 months           1,689              31 (1.8)                  1.38 (0.72 -- 2.64)              0.327
   Ever                     6,270              96 (1.5)                  0.93 (0.60 -- 1.42)              0.730
  Blood transfusion                                                                                        
   Never                    18,122             196 (1.1)                 1.0                              \-
   Past 12 months           256                10 (3.9)                  1.45 (0.65 -- 3.21)              0.365
   Ever                     843                24 (2.9)                  1.83 (1.01 -- 3.30)              0.043
  Hospitalization                                                                                          
   Never                    13,095             143 (1.1)                 1.0                              \-
   Past 12 months           1,308              25 (1.9)                  1.87 (1.04 -- 3.38)              0.037
   Ever                     5,032              67 (1.3)                  1.46 (0.97 -- 2.19)              0.065
  Endoscopy                                                                                                
   Never                    16,695             190 (1.1)                 1.0                              \-
   Past 12 months           904                13 (1.4)                  1.14 (0.53 -- 2.47)              0.729
   Ever                     1,785              29 (1.6)                  1.17 (0.64 -- 2.15)              0.615
  Tatoo                                                                                                    
   No                       18,034             202 (1.1)                 1.0                              \-
   Yes                      1,459              33 (2.3)                  1.63 (0.95 -- 2.80)              0.076
  Body piercing                                                                                            
   No                       17,859             215 (1.2)                 1.0                              \-
   Yes                      1,634              20 (1.2)                  0.97 (0.51 -- 1.87)              0.935
  Health-care related job                                                                                  
   No                       15,424             195 (1.3)                 1.0                              \-
   Yes                      1,206              20 (1.7)                  0.91 (0.46 -- 1.80)              0.783

\* Adjusted for random effect and age weighted by age groups and regions.

###### 

Age-adjusted odds ratio of hepatitis C infection for sexual behavioral-related factors in the urban Brazilian population

  **Risk factors**                         **Participants**   **HCV infection n (%)**   **OR**~**adjusted**~**(95% CI)\***   **p-value**
  ---------------------------------------- ------------------ ------------------------- ------------------------------------ -------------
  Initiated sexual life                                                                                                       
   No                                      4,137              36 (0.9)                  1.0                                  \-
   Yes                                     12,468             179 (1.4)                 0.97 (0.56 -- 1.68)                  0.912
  Condom use                                                                                                                  
   Always                                  3,831              37 (1.0)                  1.0                                  \-
   Sometimes                               1,944              29 (1.5)                  1.71 (0.85 -- 3.43)                  0.132
   Never                                   6,077              103 (1.7)                 1.04 (0.56 -- 1.96)                  0.888
  Current partner had hepatitis                                                                                               
   No                                      10,263             140 (1.4)                 1.0                                  \-
   Yes                                     445                13 (2.9)                  2.16 (1.00 -- 4.65)                  0.050
  Bisexual partner                                                                                                            
   No                                      11,417             158 (1.4)                 1.0                                  \-
   Yes                                     276                4 (1.4)                   0.83 (0.29 -- 2.42)                  0.737
  Unknown                                  775                17 (2.2)                  1.41 (0.69 -- 2.87)                  0.343
   Sexual partners with STD                                                                                                   
   No                                      11,086             164 (1.5)                 1.0                                  \-
   Yes                                     819                10 (1.2)                  0.43 (0.20 -- 0.93)                  0.031
  Previous STD                                                                                                                
   No                                      11,079             153 (1.4)                 1.0                                  \-
   Yes                                     1,301              25 (1.9)                  0.96 (0.50 -- 1.83)                  0.901
  Another sexual partner besides current                                                                                      
   No                                      4,703              64 (1.4)                  1.0                                  \-
   Yes                                     6,978              101 (1.4)                 1.10 (0.73 -- 1.65)                  0.657

\* Adjusted for random effect and age weighted by age groups and regions.

###### 

Age-adjusted odds ratio of hepatitis C infection for drug use-related factors in the urban Brazilian population

  **Risk factors**                **Participants**   **HCV infection n (%)**   **OR**~**adjusted**~**(95% CI)\***   **p-value**
  ------------------------------- ------------------ ------------------------- ------------------------------------ -------------
  Ever use of smoked drugs                                                                                           
   No                             14,726             177 (1.2)                 1.0                                  \-
   Yes                            1,839              38 (2.1)                  1.47 (0.88 -- 2.46)                  0.141
  Ever use of inhalated drugs                                                                                        
   No                             16,293             206 (1.3)                 1.0                                  \-
   Yes                            265                09 (3.4)                  2.68 (0.85 -- 8.45)                  0.093
  Ever use of sniffed drugs                                                                                          
   No                             15,827             189 (1.2)                 1.0                                  \-
   Yes                            749                25 (3.3)                  3.50 (1.87 -- 6.54)                  0.000
  Ever use of injected drugs                                                                                         
   No                             16,463             204 (1.2)                 1.0                                  \-
   Yes                            70                 11 (15.7)                 12.79 (5.19 -- 31.5)                 0.000
  Injections with glass syringe                                                                                      
   No                             13,450             148 (1.1)                 1.0                                  \-
   Yes                            2,931              63 (2.2)                  1.67 (1.09 -- 2.56)                  0.019
  Alcohol consumption                                                                                                
   None                           10,237             129 (1.3)                 1.0                                  \-
   Light consumption              5,376              67 (1.2)                  0.75 (0.50 -- 1.12)                  0.155
   Heavy consumption              978                16 (1.6)                  0.84 (0.41 -- 1.69)                  0.619
   Dependent                      41                 03 (7.3)                  2.88 (0.79 -- 10.49)                 0.108

\* Adjusted for random effect and age weighted by age groups and regions.

The multivariate analysis shows that a history of injected drug use (OR = 6.65; 95% CI 2.47--17.91) and sniffed drug use (OR = 2.59; 95% CI 1.34--5.81) were strongly associated to HCV infection. Other risk factors were the use of a glass syringe (OR = 1.52; 95% CI 0.97--2.36) and ever-hospitalization, both with a borderline p value. A proxy measure of socioeconomic conditions (sewage disposal) was also associated with testing positive for anti-HCV. Age, introduced in the model as a continuous variable, showed that there was an increase in the likelihood of becoming infected of 0.02% for each year of life (OR = 1.02; 95% CI 1.01--1.04 (Table [5](#T5){ref-type="table"}). The proportion of cases attributable to each variable in the final multivariate model ranged from 4.2% to 10.2%, and the proportion attributable to all factors together was 39.9%.

###### 

Multivariate analysis of hepatitis C infection for potential risk factors and estimated population attributable risk in the urban Brazilian population

  **Factors associated**         **OR**~**adjusted**~**(95% CI)\***   **p-value**   **Population Arributable risk %**
  ------------------------------ ------------------------------------ ------------- -----------------------------------
  Age                            1.02 (1.01 -- 1.04)                  0.001         \-
  Ever use of injected drugs                                                         
   No                            1.0                                  \-             
   Yes                           6.65 (2.47 -- 17.91)                 \< 0.0001     4.3
  Ever use of sniffed drugs                                                          
   No                            1.0                                  \-             
   Yes                           2.59 (1.34 -- 5.01)                  0.005         7.2
  Injection with glass syringe                                                       
   No                            1.0                                  \-             
   Yes                           1.52 (0.97 -- 2.36)                  0.065         10.2
  Hospitalization                                                                    
   Never                         1.0                                  \-             
   Past 12 months                1.90 (1.03 -- 3.51)                  0.040         5.0
   Ever                          1.44 (0.94 -- 2.21)                  0.094         8.7
  Sewage disposal                                                                    
   Public system                 1.0                                  \-             
   Septic tank                   1.39 (0.91 -- 2.12)                  0.125         8.8
   Other destination             2.53 (1.38 -- 4.65)                  0.003         3.9
                                                                                    39.9\*\*

\* Adjusted for random effect and age weighted by age groups and regions.

\*\* Summary population attributable risk.

Discussion
==========

This first Brazilian nationwide hepatitis survey showed 1.38% HCV positivity in a representative sample of 19,503 adolescents and adults in all macro-regions. Approximately 1.3 million individuals would be expected to be anti-HCV-positive in the country under the assumption of similar anti-HCV antibody prevalence for the Brazilian population as a whole (population of 169.8 million, as of 2000). The current population-based survey detected a lower prevalence of anti-HCV antibody than that previously reported by the WHO for the country \[[@B2]\], shifting from intermediate to low prevalence.

The few nationwide population-based studies have reported prevalence of anti-HCV antibodies of 1.3% in the USA \[[@B6]\] and 1.0% in France \[[@B27]\], which are similar to that found in this study. An increase in anti-HCV prevalence with age was found in the large census surveys conducted in the USA. Peak HCV prevalence was found among adults aged 30-49 years in the first census survey (1988--1994), shifting to 40--49 years in the later surveys (1999--2002; 2003--2006; 2007--2008) \[[@B6]\]. Although our results also showed increased HCV exposure with age, the peak prevalence was observed in the older age group. Increased HCV infection among the adult population has also been reported in selected regions of Brazil \[[@B11],[@B13]\] and among first-time blood donors \[[@B28]\].

The highest prevalence of the HCV marker (2.1%) was in the North macro-region of Brazil, which is below the 2.5% prevalence threshold for low endemicity according to WHO criteria \[[@B2]\]. However, most of the estimated infected individuals resided in the Southeast region (\~220,000), since approximately 14 million individuals aged 10 to 69 years live in these highly urbanized State capitals that include the cities of Sao Paulo and Rio de Janeiro. The burden of infection in absolute terms thus has an uneven geographical distribution, concentrated in the South and Southeast macro-regions. According to the official surveillance system, the residents of the southeast and south had higher HCV detection rates (above the national figures) than the residents in the north, northeast and central-west from 2003 through 2009 (unpublished data). One likely explanation for the higher detection rates in the south and southeast may be better access to and organization of the health system of these regions \[[@B29]\]. The surveillance data for HCV may also underestimate the prevalence of HCV infection in the country as a whole, in view of the prevalence found by this population-based survey. Under-reporting of HCV infection by other national surveillance systems has also been discussed for Europe \[[@B30],[@B31]\] and for the USA \[[@B32]\], pointing to the need for updated population-based studies for public health purposes.

Interestingly, those participating in this national survey showed similarities in terms of the risk profile for HCV acquisition, with slightly higher frequencies for blood transfusion (7.8%), tattoos (12.2%) and sniffed drugs (5.9%) in the south macro-region (data not shown). In this household survey, injected and sniffed drug use was strongly associated with HCV antibodies in multivariate analysis. These findings accord with the literature regarding injected drug use as the main source of transmission of HCV infection in developed countries and with the reports of sniffed drugs as another important mode of HCV acquisition in developing countries, as previously reported in selected Brazilian populations \[[@B33]\]. In the present survey, a history of previous hospitalization and use of injections with glass syringe not related to drug use were also associated with HCV seropositivity, both of which have been widely reported as epidemiological risk factors for HCV infection worldwide \[[@B1],[@B2]\]. In our survey, a socioeconomic marker of extreme poverty (no sewage disposal) remained associated with anti-HCV prevalence (OR = 2.53), after adjusting for confounding factors. Although there is no biological plausibility for social deprivation and increased risk of HCV infection, the former may be a surrogate marker for being at risk for HCV transmission. In a countrywide survey in France, social factors remained associated with HCV infection after adjusting for known risk factors as in our study. Nevertheless, having ever used drugs, having tattoos, and having being incarcerated were correlated with social deprivation \[[@B8]\]. The USA HCV prevalence survey also reported a correlation of infection by drug use with low family income, high number of sex partners, and non-injected drug use \[[@B5]\]. Furthermore, studies using cross-sectional designs such as our survey cannot sort out the temporal relationships between the potential risk factors and the outcomes.

The estimated population attributable risk indicates that the risk factors identified explain approximately 40% of all cases of infection. The higher population attributable risk percent found for "ever use of sniffed drugs" (7.2%) than for "ever use of injected drugs" (4.3%) was probably due to the lower frequency of IDUs than of sniffed drug users in the studied population. Although we cannot evaluate to what extent there was an underreporting of injection drug use because of stigma and discrimination in our study, the frequencies we found (data not shown) seem consonant with the national survey conducted by the Brazilian Center of Information on Psychotropic drugs (CEBRID) and a study among hospitalized patients \[[@B34],[@B35]\]. In relation to IDU, as the population attributable risk is related to the general population (injecting and non-injecting drug users), the attributable risk among the exposed (injecting drug users) will be greater and therefore the proportion of infection in that group that could be prevented by eliminating the exposure would be larger among IDUs.

One limitation of this survey is that it included a sampling of the capital cities of the five Brazilian macro-regions and the Federal District and was not designed as part of a census survey \[[@B22]\] as was NHANES \[[@B3]\]. Therefore, the low prevalence of anti-HCV detected in all macro-regions may not reflect the levels of infection outside the study settings, such as in rural areas, and specific pockets. Since this investigation was planned as a population study, specific high-risk groups for HCV acquisition, such as institutionalized or incarcerated individuals, were excluded. Therefore, the prevalence reported here should be considered a conservative estimate of anti-HCV prevalence.

It should be noted that, in view of the low frequency of HCV antibodies for the country as a whole, the risk factor analysis was performed for the entire data set and not by macro-region. This had been anticipated by the study protocol \[[@B22]\].

Another methodological issue regarding the interpretation of our findings is that a sole marker of HCV infection may lead to misclassification, owing to false positive results. However, it would be a non-differential misclassification, underestimating the associations reported. For this reason, the strength of association may also be conservative \[[@B36]\]. We acknowledge that the approximately 40% of HCV-RNA positivity among anti-HCV positive individuals was lower than expected. Potential explanations for this are poor specificity of the anti-HCV antibody assay, poor sensitivity of the HCV-RNA assay, or a true biologically higher HCV-RNA spontaneous clearance rate in the Brazilian setting. In our study, high sensitivity (poor specificity) of anti-HCV was identified because of the cutoff point recommended by the manufacturer; this may have increased false positive rates. In this regard, the ROC curve showed that a cutoff point of OD =4.0 yielded higher specificity on the detection of viremia. The assay used (AMPLICOR™ Roche Version 2.0) for HCV-RNA testing detects 60 International Units per ml. A concern on the detection of hepatitis C virus RNA in a large population survey is the specimen handling and storage. Nevertheless, we have followed the laboratory procedures and storage recommendations and all tests were performed in a reference laboratory where quality control was assured. In addition, data analysis showed that the frequency of viremia found was consistent across macro-regions. In general, about 25% of infected HCV individuals have spontaneous viral clearance. A systematic review of longitudinal studies on spontaneous viral clearance showed that clearance was more frequent in females and in acute clinical hepatitis C infection \[[@B37]\]. Furthermore, a genome-wide association study showed that individuals with favorable *IL28B* genotypes are more likely to clear HCV infection than are those with unfavorable alleles, which could have implications in viral clearance ability among different ethnic groups \[[@B38]\]. In the South of Brazil, IL28B polymorphism was associated with spontaneous clearance of hepatitis C infection among co-infected HCV and HIV/AIDS patients \[[@B39]\].

Although this survey covered a large geographical area and enrolled a large population sample in all State Capitals and Federal District, there was low refusal rate in all macro-regions, which was slightly higher in the wealthier regions: South and Southeast. This indicates the feasibility of nationwide-studies.

In this survey, subtypes 1a, 1b, 2b and 3a were detected in the general Brazilian population within the macro-regions. Overall, genotype 1 was predominant, as reported in the literature, which suggests that genotype 1a and 1b are the most frequent HCV genotypes worldwide, accounting for 60% of the infections \[[@B2]\]. The geographical distribution of hepatitis C virus genotypes in Brazil among a large sample of chronic hepatitis C patients from all regions has also shown a predominance of genotype 1 followed by genotype 3 \[[@B19]\], in accordance with our findings. Among injecting drug-users, the circulating subtypes were 1 and 3 in the studies conducted between 1994--1997 and 1999--2001 in Rio de Janeiro \[[@B40]\]. Our study was not designed to identify the diversity of HCV genotypes among the regions. We are aware that not all anti-HCV positive individuals were tested for HCV-RNA, which may limit the extrapolation of these results.

Conclusions
===========

The present survey measured the hepatitis C infection prevalence among the general population for the country and macro-regions, and classifies Brazil as a low-endemicity area. Nevertheless, the large estimated absolute numbers of infected individuals indicate the burden of the disease in the near future. This implies costs for the health-care system and society as a whole, as pointed out in other studies \[[@B41],[@B42]\]. This issue needs to be addressed by studies that evaluate the economic impact of HCV infection. The known risk factors explain less than 50% of the infected cases, limiting the prevention strategies. Nevertheless, our findings regarding risk behaviors associated with HCV infection showed that there is still room for improving strategies for reducing transmission among drug users. Another recommendation would be to study the extent to which nosocomial transmission is occurring in our setting. Finally, there is a need for targeting individuals living in poverty, in view of the evidence found of an association between infection and social deprivation.
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